Vivos Therapeutics, Inc. (VVOS) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held on August 25, 2022. The filing date is August 26, 2022. Vivos Therapeutics, Inc. is a Delaware corporation listed on The NASDAQ Stock Market LLC and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The Annual Meeting addressed two primary proposals:
- Proposal 1: Election of Directors
- Stockholders elected six directors for one-year terms: Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, Dr. Matthew Thompson, and R. Kirk Huntsman.
- Voting Statistics: 23,012,119 shares were entitled to vote. 14,884,738 shares were present or represented by proxy, constituting a quorum.
- Results: All nominees were elected. However, a significant portion of shares were withheld for each nominee (ranging from approximately 3.28 million to 3.56 million shares withheld). Broker non-votes totaled 5,023,863 shares for all director nominees.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of Plante & Moran, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Results: 7,372,456 shares voted for, 3,812,172 shares voted against, and 3,700,110 shares abstained. There were no broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the high number of shares withheld for director nominees (approx. 3.3M to 3.6M per nominee) to assess shareholder sentiment regarding the board.
- Confirm the total number of shares outstanding (23,012,119) against the most recent 10-K or 10-Q filings to ensure capital structure consistency.
- Review the proxy statement for the 2022 Annual Meeting to understand the context behind the significant "against" votes (3.8M) and abstentions (3.7M) on the auditor ratification.
- Check subsequent filings for any changes in the board composition or auditor status following this meeting.